Mazdutide
most data
The Dose Guy’s verdictSep 1, 20262 sources
Mazdutide is a legitimate weight-loss drug with strong trial numbers and a Chinese approval to its name. The question isn’t whether it works, it clearly does, but whether there’s a reason to choose it when retatrutide and tirzepatide are on the same shelf. For most people with gray-market access to all of them, the answer is no: retatrutide out-performs it and tirzepatide has a gentler ride and deeper outcome data. Mazdutide’s real niche is availability. It’s easier to source in some markets, and the US trial program may eventually give it a distinct regulatory lane.
What it is
One peptide, two receptors. Mazdutide is a dual agonist hitting GLP-1 and glucagon. The GLP-1 arm does the familiar work: slowing the gut, quieting appetite, improving insulin signaling. The glucagon arm adds energy expenditure, pushing the body to burn more at rest, the same mechanism that gives retatrutide its extra edge over tirzepatide. The difference is that retatrutide hits GIP as a third receptor while mazdutide doesn’t. Mechanically, mazdutide is closer to survodutide, another GLP-1/glucagon dual agonist, than to either of the top-shelf compounds.
Innovent Biologics developed it in China and is building a US program. The numbers translate: this isn’t a regional curiosity, it’s a real drug with data behind it.
What the research shows
Deep for a compound most Western users haven’t heard of. Multiple phase 3 trials, a US program, and a Chinese approval:
Realistic protocols
Same class, same principles. Dose to your hunger, not to a calendar. The right dose is the lowest one that keeps appetite quiet, found from below, and held there for as long as it works. Mazdutide titrates in monthly steps the way the trials did it, and the gut side effects cluster around dose increases, so patience on the ramp pays off.
Alcohol: the same warning as every incretin. A slowed gut plus alcohol equals nausea, and most people on this class find drinking stops being fun. Skip it or go very easy.
No head-to-head against tirzepatide exists. Reading the trial programs side by side, the GI profile looks rougher at comparable doses. If you titrate slowly and still can’t tolerate the gut effects, switching to tirzepatide is a reasonable move. You trade some ceiling for a smoother ride.
Protect lean mass with high protein and resistance training on a cut this fast. If the appetite grip fades after months, cagrilintide is the community’s add-on.
The trial doses run 3, 4, 6, and 9 mg weekly, with exploratory data at 16 mg. The community protocol mirrors the trials because gray-market dosing guidance for mazdutide is thin compared to semaglutide or the other established incretins.
Side effects
The GI ride looks rougher than the established incretins at comparable weight-loss levels, a cross-trial read, not a head-to-head:
